XCRT Quote, Financials, Valuation and Earnings

American Shared Hospital Services has a net margin of -- compared to Xcelerate's net margin of -2.96%. Xcelerate's return on equity of -- beat American Shared Hospital Services's return on equity of 13.75%.

Xcelerate has a consensus price target of --, signalling downside risk potential of --. On the other hand American Shared Hospital Services has an analysts' consensus of -- which suggests that it could grow by 42.41%. Given that American Shared Hospital Services has higher upside potential than Xcelerate, analysts believe American Shared Hospital Services is more attractive than Xcelerate.

Xcelerate has a beta of 3.268, which suggesting that the stock is 226.758% more volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.289%.

Xcelerate has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xcelerate pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.

Xcelerate quarterly revenues are --, which are smaller than American Shared Hospital Services quarterly revenues of $7M. Xcelerate's net income of -- is lower than American Shared Hospital Services's net income of -$207K. Notably, Xcelerate's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 5.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate is -- versus 0.82x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -- compared to Xcelerate's net margin of 13.04%. Xcelerate's return on equity of -- beat Cryo-Cell International's return on equity of --.

Xcelerate has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International has an analysts' consensus of -- which suggests that it could grow by 16.13%. Given that Cryo-Cell International has higher upside potential than Xcelerate, analysts believe Cryo-Cell International is more attractive than Xcelerate.

Xcelerate has a beta of 3.268, which suggesting that the stock is 226.758% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Xcelerate has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.23% to investors and pays a quarterly dividend of $0.25 per share. Xcelerate pays -- of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Xcelerate quarterly revenues are --, which are smaller than Cryo-Cell International quarterly revenues of $8.1M. Xcelerate's net income of -- is lower than Cryo-Cell International's net income of $1.1M. Notably, Xcelerate's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate is -- versus 2.01x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

National Healthcare has a net margin of -- compared to Xcelerate's net margin of 12.58%. Xcelerate's return on equity of -- beat National Healthcare's return on equity of 13.34%.

Xcelerate has a consensus price target of --, signalling downside risk potential of --. On the other hand National Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that Xcelerate has higher upside potential than National Healthcare, analysts believe Xcelerate is more attractive than National Healthcare.

Xcelerate has a beta of 3.268, which suggesting that the stock is 226.758% more volatile than S&P 500. In comparison National Healthcare has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.415%.

Xcelerate has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Healthcare offers a yield of 2.42% to investors and pays a quarterly dividend of $0.61 per share. Xcelerate pays -- of its earnings as a dividend. National Healthcare pays out 53.24% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Xcelerate quarterly revenues are --, which are smaller than National Healthcare quarterly revenues of $340.2M. Xcelerate's net income of -- is lower than National Healthcare's net income of $42.8M. Notably, Xcelerate's price-to-earnings ratio is -- while National Healthcare's PE ratio is 12.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate is -- versus 1.26x for National Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of -- compared to Xcelerate's net margin of -23.24%. Xcelerate's return on equity of -- beat Regional Health Properties's return on equity of -489.72%.

Xcelerate has a consensus price target of --, signalling downside risk potential of --. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 161.04%. Given that Regional Health Properties has higher upside potential than Xcelerate, analysts believe Regional Health Properties is more attractive than Xcelerate.

Xcelerate has a beta of 3.268, which suggesting that the stock is 226.758% more volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.677%.

Xcelerate has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xcelerate pays -- of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend.

Xcelerate quarterly revenues are --, which are smaller than Regional Health Properties quarterly revenues of $4.2M. Xcelerate's net income of -- is lower than Regional Health Properties's net income of -$982K. Notably, Xcelerate's price-to-earnings ratio is -- while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate is -- versus 0.27x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.